viewCentrexion Therapeutics Corp

IPO Roundup: Non-opioid pain treatment developer Centrexion Therapeutics set to IPO

The Massachusetts-based biopharma is led by former Pfizer CEO Jeffrey B. Kindler

IPO and gold coins
Two blank-check companies and two fintech companies plan to price shares as well

A total of six companies will price their shares this week, including two blank-check companies, two biopharmas and two fintech-related companies.


Vapotherm Inc (NYSE:VAPO) will be one of the first initial public offerings of the week. The New Hampshire-based company develops non-invasive breathing aids for those with respiratory distress. The company was founded about 25 years ago and reported $41 million in revenue for the year as of September 2018. Vapotherm plans to offer 4 million shares priced between $14 and $16, raising up to $64 million.


Weidai Ltd (NYSE:WEI) is one of two fintech IPOs on deck for this week. The China-based company operates a platform that provides auto-secured loans for small businesses in China. Founded in 2011, the company reported $565 million in revenue for the year as of June 2018. Weidai plans to offer 4.5 million shares priced between $9 and $11, raising up to $49.5 million.

READ: OPKO Health sees prescriptions for Rayaldee triple in third quarter

Centrexion Therapeutics Corp (NASDAQ:CNTX) is the first biopharma set to price its shares this week. The Massachusetts-based company specializes in developing non-opioid pain treatments. The biopharma is led by former Pfizer Inc (NYSE:PFE) CEO Jeffrey B. Kindler. Centrexion Therapeutics plans to offer 5 million shares priced between $14 and $16, raising up to $80 million.


Taiwan Liposome Company Ltd (NASDAQ:TLC) is the second biopharma of the week gearing up to go public. The clinical-stage specialty pharmaceutical company develops nanomedicines for pain and eye diseases. The Taiwan-based company plans to offer 5 million ADS shares priced at $5.80, lower than its initial offer of 4.7 million shares priced at $7.46. The company could raise as much as $29 million.

Fintech Acquisition Corp III (NASDAQ:FTACU) will price its shares at the end of the week. The blank-check company was formed to acquire fintech businesses. The Philadelphia-based company was formed by the management of Bancorp, which provides private label banking and technology services. The company will offer 27.5 million shares priced at $10, raising up to $275 million.

AMCI Acquisition Corp (NASDAQ:AMCIU) is the second blank-check company pricing shares this week. The special acquisition company said it will focus on the global natural resources sector. AMCI will offer 20 million shares priced at $10 each. The company could raise as much as $200 million in its IPO.


Contact Lenore Fedow at [email protected]

Follow her on Twitter@LenoreMariee


Quick facts: Centrexion Therapeutics Corp

Price: - -

Market: NASDAQ
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Proactive One2One Virtual Event - FansUnite Entertainment

FansUnite Entertainment Inc (CSE:FANS) (OTCMKTS:FUNFF) CEO Scott Burton and President Darius Eghdami present to investors at Proactive's One2One Virtual Event. The company focuses on technology related to regulated and lawful online sports betting and other related products.

26 minutes ago

3 min read